Georgina V Long

Summary

Publications

  1. doi request reprint Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression
    Georgina V Long
    Melanoma Institute Australia, Sydney, NSW, Australia
    Pigment Cell Melanoma Res 26:499-508. 2013
  2. doi request reprint Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma
    Georgina V Long
    Melanoma Institute Australia and Westmead Hospital, 40 Rocklands Rd, North Sydney, NSW 2060, Australia
    Am J Surg Pathol 37:61-5. 2013
  3. doi request reprint Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
    Georgina V Long
    Melanoma Institute Australia, Westmead Institute for Cancer Research, and Westmead Hospital, The University of Sydney, Sydney, NSW, Australia
    Lancet Oncol 13:1087-95. 2012
  4. doi request reprint Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma
    Georgina V Long
    Melanoma Institute Australia, 40 Rocklands Rd, North Sydney, New South Wales, 2060, Australia
    J Clin Oncol 29:1239-46. 2011
  5. doi request reprint Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma
    James S Wilmott
    Melanoma Institute Australia, Sydney, NSW, Australia
    Clin Cancer Res 18:1386-94. 2012
  6. doi request reprint BRAF inhibitor activity in V600R metastatic melanoma
    Oliver Klein
    Melanoma Institute Australia and Westmead Hospital, University of Sydney, 40 Rocklands Road, North Sydney, New South Wales, Australia
    Eur J Cancer 49:1073-9. 2013
  7. doi request reprint Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma
    Alexander M Menzies
    Melanoma Institute Australia, Disciplines of Medicine, Surgery, Pathology, and Westmead Institute for Cancer Research, Westmead Millennium Institute, The University of Sydney, Sydney, New South Wales, Australia
    Clin Cancer Res 18:3242-9. 2012
  8. doi request reprint Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine
    James S Wilmott
    Melanoma Institute Australia, Australia
    Mol Cancer Ther 11:2704-8. 2012
  9. pmc Dabrafenib and its potential for the treatment of metastatic melanoma
    Alexander M Menzies
    Melanoma Institute Australia, Sydney, New South Wales, Australia
    Drug Des Devel Ther 6:391-405. 2012
  10. doi request reprint (18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma
    Matteo S Carlino
    Westmead Millennium Institute, The University of Sydney, Sydney, Australia
    Eur J Cancer 49:395-402. 2013

Detail Information

Publications23

  1. doi request reprint Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression
    Georgina V Long
    Melanoma Institute Australia, Sydney, NSW, Australia
    Pigment Cell Melanoma Res 26:499-508. 2013
    ..The addition of therapies targeting the cell cycle machinery may improve the response and duration of BRAFi, and investigation of the mechanisms of apoptosis may provide additional therapeutic targets. ..
  2. doi request reprint Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma
    Georgina V Long
    Melanoma Institute Australia and Westmead Hospital, 40 Rocklands Rd, North Sydney, NSW 2060, Australia
    Am J Surg Pathol 37:61-5. 2013
    ..Clinical use of the V600E BRAF antibody should be a valuable supplement to conventional mutation testing and allow V600E mutant metastatic melanoma patients to be triaged rapidly into appropriate treatment pathways...
  3. doi request reprint Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
    Georgina V Long
    Melanoma Institute Australia, Westmead Institute for Cancer Research, and Westmead Hospital, The University of Sydney, Sydney, NSW, Australia
    Lancet Oncol 13:1087-95. 2012
    ..We assessed dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain...
  4. doi request reprint Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma
    Georgina V Long
    Melanoma Institute Australia, 40 Rocklands Rd, North Sydney, New South Wales, 2060, Australia
    J Clin Oncol 29:1239-46. 2011
    ..To assess the frequency and type of oncogenic BRAF mutations in metastatic melanoma and correlate BRAF status with clinicopathologic features and outcome...
  5. doi request reprint Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma
    James S Wilmott
    Melanoma Institute Australia, Sydney, NSW, Australia
    Clin Cancer Res 18:1386-94. 2012
    ..To evaluate the effects of treatment with the potent mutant BRAF inhibitors GSK2118436 or vemurafenib (PLX4720) on immune responses to metastatic melanoma in tissues taken before and after treatment...
  6. doi request reprint BRAF inhibitor activity in V600R metastatic melanoma
    Oliver Klein
    Melanoma Institute Australia and Westmead Hospital, University of Sydney, 40 Rocklands Road, North Sydney, New South Wales, Australia
    Eur J Cancer 49:1073-9. 2013
    ..Our experience suggests that patients with V600R BRAF mutations can be treated successfully with oral BRAF inhibitors, and molecular diagnostic assays should include detection of this type of mutation...
  7. doi request reprint Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma
    Alexander M Menzies
    Melanoma Institute Australia, Disciplines of Medicine, Surgery, Pathology, and Westmead Institute for Cancer Research, Westmead Millennium Institute, The University of Sydney, Sydney, New South Wales, Australia
    Clin Cancer Res 18:3242-9. 2012
    ..Methods: A prospectively assembled cohort of Australian patients were followed from diagnosis of metastatic melanoma (N = 308). Clinicopathologic variables were correlated with BRAF mutational status, genotype, and survival...
  8. doi request reprint Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine
    James S Wilmott
    Melanoma Institute Australia, Australia
    Mol Cancer Ther 11:2704-8. 2012
    ....
  9. pmc Dabrafenib and its potential for the treatment of metastatic melanoma
    Alexander M Menzies
    Melanoma Institute Australia, Sydney, New South Wales, Australia
    Drug Des Devel Ther 6:391-405. 2012
    ..It is expected that new combinations of targeted drugs, such as the combination of dabrafenib and trametinib (GSK1120212, a MEK inhibitor), will provide higher response rates and more durable clinical benefit than dabrafenib monotherapy...
  10. doi request reprint (18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma
    Matteo S Carlino
    Westmead Millennium Institute, The University of Sydney, Sydney, Australia
    Eur J Cancer 49:395-402. 2013
    ..We aim to determine the prevalence, and clinicopathologic correlates of intra-patient heterogeneity of FDG-PET response in metastatic melanoma treated with dabrafenib, and to determine whether heterogeneity predicts clinical outcome...
  11. doi request reprint Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma
    Rajmohan Murali
    Melanoma Institute Australia, Sydney, New South Wales, Australia
    Cancer 118:4519-29. 2012
    ..The authors sought to address the latter question in the current study...
  12. doi request reprint Intrapatient Homogeneity of BRAFV600E Expression in Melanoma
    Alexander M Menzies
    Melanoma Institute Australia Discipline of Medicine Pathology Surgery, The University of Sydney Departments of Melanoma and Surgical Oncology Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital Department of Medicine, Westmead Hospital Westmead Institute for Cancer Research, Westmead Hospital The Kinghorn Cancer Centre, Garvan Institute of Medical Research St Vincent s Clinical School, University of New South Wales, Sydney, Australia
    Am J Surg Pathol 38:377-82. 2014
    ....
  13. doi request reprint Cutaneous toxicities of RAF inhibitors
    Rachael Anforth
    Department of Dermatology, Westmead Hospital, Sydney, NSW, Australia
    Lancet Oncol 14:e11-8. 2013
    ..These disorders often affect patients' quality of life; therefore, dermatological assessment and timely management is essential to ensure that patients continue to use RAF inhibitors...
  14. doi request reprint Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma
    Rajmohan Murali
    Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia
    Ann Surg Oncol 19:1782-9. 2012
    ..We sought to identify clinical and pathologic factors associated with distant metastasis and survival in a large number of patients with thin melanoma treated at a single institution...
  15. doi request reprint Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib
    Mary W F Azer
    Westmead Hospital, Westmead, Australia Melanoma Institute Australia, Sydney, Australia
    Cancer 120:530-6. 2014
    ..This study sought to examine the intracranial (IC) and extracranial (EC) patterns of response and progression in patients with active melanoma brain metastases treated with dabrafenib...
  16. pmc Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma
    Alexander M Menzies
    Melanoma Institute Australia, Sydney, Australia The University of Sydney, Sydney, Australia
    PLoS ONE 9:e85004. 2014
    ..We sought to examine the patterns of response and progression in patients treated with targeted therapy...
  17. doi request reprint Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma
    Matteo S Carlino
    Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, NSW 2145, Australia
    Mol Cancer Ther 12:1332-42. 2013
    ..These data provide a rationale for the continuation of BRAF and MEK inhibitors after disease progression and support the development of clinical trials to examine this strategy...
  18. doi request reprint Diagnosis and treatment of KIT-mutant metastatic melanoma
    Megan Lyle
    Melanoma Institute Australia, Sydney, New South Wales, Australia
    J Clin Oncol 31:3176-81. 2013
    ..However, Sanger sequencing of KIT exons 9, 11, 13, and 17, performed as screening for a clinical trial enrolling patients with metastatic acral and mucosal melanomas, showed an exon 13 K642E mutation. ..
  19. doi request reprint Paradoxical oncogenesis: are all BRAF inhibitors equal?
    Alexander M Menzies
    Melanoma Institute Australia, Sydney, NSW, Australia
    Pigment Cell Melanoma Res 26:611-5. 2013
    ....
  20. doi request reprint Treatment of melanoma brain metastases: a new paradigm
    Matteo S Carlino
    Westmead Institute for Cancer Research, Westmead Millennium Institute, Sydney, Australia
    Cancer J 18:208-12. 2012
    ..We present a new treatment algorithm for melanoma patients with brain metastases, which integrates the evolving evidence for the use of BRAF inhibitors...
  21. doi request reprint Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care
    Richard A Scolyer
    Melanoma Institute Australia, Sydney, NSW, Australia
    Mol Oncol 5:124-36. 2011
    ..Whilst there remains much to be discovered in this rapidly evolving field, there is already great optimism that more rational and effective therapies for melanoma patients will soon be widely available...
  22. doi request reprint The role of systemic therapies in the management of melanoma brain metastases
    Megan Lyle
    aMelanoma Institute Australia bThe University of Sydney, Sydney, Australia
    Curr Opin Oncol 26:222-9. 2014
    ..This review will focus on new systemic therapies for metastatic melanoma and their evolving role in the management of brain metastases...
  23. doi request reprint Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond
    Alexander M Menzies
    Melanoma Institute Australia, Sydney, Australia The University of Sydney, Sydney, Australia
    Eur J Cancer 49:3229-41. 2013
    ....